Key result
Novel oral anticoagulants are emerging as alternatives to warfarin and heparin, requiring interventional radiologists to understand their profiles for appropriate periprocedural management.
Why the study?
There has been a heavy dependency on warfarin and heparin for anticoagulation for 60 years, but the emergence of novel oral anticoagulants is likely to change this.
This review provides interventional radiologists with an update on novel oral anticoagulants and proposes guidelines for their periprocedural management.
OBJECTIVE: Thromboembolic disorders are leading causes of morbidity and mortality, with treatment and prophylaxis a priority. There has been a heavy dependency upon warfarin and heparin for anticoagulation for 60 years. This is likely to change with the emergence of novel oral anticoagulants. CONCLUSION: Interventional radiologists are increasingly encountering these medications, and a thorough knowledge of them is essential for appropriate periprocedural management. This article will review these novel agents, their uses, and their pharmacologic profiles and will propose guidelines for periprocedural management.
No takes yet. Share an insight, caveat, or question.
Crockett et al. (2012) conducted a review in Thromboembolic disorders. Novel oral anticoagulants vs. Warfarin and heparin was evaluated. Novel oral anticoagulants are emerging as alternatives to warfarin and heparin, requiring interventional radiologists to understand their profiles for appropriate periprocedural management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: